Re: The Mouse Lethality Assay for Botulinum Toxin Products

Pickett A. (2012). The botulinum toxin LD50 potency assay — another chapter, another mystery. ATLA 40, 221–223.

Adler S. , Bicker G. , Bigalke H. , Bishop C. , Blümel J. , Dressler D. , Fitzgerald J. , Gessler F. , Heuschen H. , Kegel B. , Luch A. , Milne C. , Pickett A. , Ratsch H. , Ruhdel I. , Sesardic D. , Stephens M. , Stiens G. , Thornton P.D. , Thürmer R. , Vey M. , Spielmann H. , Grune B. , & Liebsch M. (2010). The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. ATLA 38, 315–330.

Fernandez-Salas E. , Wang J. , Molina Y. , Nelson J.B. , Jacky B.P. , & Aoki K.R. (2012). Botulinum neurotoxin serotype a specific cell-based potency assay to replace the mouse bioassay. PLoS One 7, e49516.

Fernandez-Salas E. (2012). Presented at Toxins 2012, Miami, Florida, USA, 5–8 December, 2012.

United States patent number 8,198,034, Immuno-based botulinum toxin serotype A activity assays, filed 13 March 2009, patent issued on 12 June 2012, serial number 12/403,531. Alexandria, VA 22313-1450, USA: Office of the Commissioner for Patents.